Prostate cancer and bone: The elective affinities

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Rucci, Nadia ^a   Angelucci, Adriano ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AMPHIREGULIN; ANGIOPOIETIN 2; ARACHIDONIC ACID; CABAZITAXEL; CATHEPSIN K; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; DENOSUMAB; DOCETAXEL; ENDOTHELIN 1; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINOLEIC ACID; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLATELET DERIVED GROWTH FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN C; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR; VASCULOTROPIN; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BONE ATROPHY; BONE LESION; BONE MARROW; BONE MARROW CELL; BONE METASTASIS; BONE MINERALIZATION; BONE REMODELING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MIGRATION; ENERGY METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HYPOCALCEMIA; INTRACELLULAR SIGNALING; JAW OSTEONECROSIS; LIFE EXPECTANCY; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TROPISM; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; BONE; BONE TUMOR; MALE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

BONE AND BONES; BONE NEOPLASMS; BONE RESORPTION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84902176089     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/167035     Document Type: Review

References (146)

1. Angelucci A., Alesse E., Molecular pathology of cancer metastasis: suggestions for future therapy. Biotargets of Cancer in Current Clinical Practice 2012 New York, NY, USA Springer 469 515
2. Saad F., Lipton A., Cook R., Chen Y., Smith M., Coleman R., Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007 110 8 1860 1867 2-s2.0-35048875471 10.1002/cncr.22991 (Pubitemid 47557312)
3. Clarke N. W., McClure J., George N. J. R., Osteoblast function and osteomalacia in metastatic prostate cancer. European Urology 1993 24 2 286 290 2-s2.0-0027255058 (Pubitemid 23246064)
4. Roudier M. P., Morrissey C., True L. D., Higano C. S., Vessella R. L., Ott S. M., Histopathological assessment of prostate cancer bone osteoblastic metastases. The Journal of Urology 2008 180 3 1154 1160 10.1016/j.juro.2008.04. 140
5. Takeuchi S., Arai K., Saitoh H., Yoshida K., Miura M., Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. Journal of Urology 1996 156 5 1691 1695 2-s2.0-0029903420 10.1016/S0022-5347(01)65484-3 (Pubitemid 26344021)
6. Leeming D. J., Hegele A., Byrjalsen I., Hofmann R., Qvist P., Karsdal M. A., Schrader A. J., Wagner R., Olbert P., Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiology Biomarkers and Prevention 2008 17 5 1269 1276 2-s2.0-52649094391 10.1158/1055-9965.EPI-07-2697
7. Seibel M. J., The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clinical Endocrinology 2008 68 6 839 849 10.1111/j.1365-2265.2007.03112.x (Pubitemid 351703933)
8. Saad F., Lipton A., Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Current Opinion in Supportive and Palliative Care 2010 4 3 127 134 10.1097/SPC.0b013e32833ac6d6
9. Lein M., Miller K., Wirth M., Weißbach L., May C., Schmidt K., Haus U., Schrader M., Jung K., Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 2009 69 6 624 632 2-s2.0-65549161868 10.1002/pros.20917
10. Olson K. B., Pienta K. J., Pain management in patients with advanced prostate cancer. Oncology 1999 13 11 1537 1550 2-s2.0-0033220402
11. Coleman R. E., Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research 2006 12 20, part 2 6243s 6249s 10.1158/1078-0432.CCR-06-0931 (Pubitemid 44703797)
12. Larson S. R., Zhang X., Dumpit R., Coleman I., Lakely B., Roudier M., Higano C. S., True L. D., Lange P. H., Montgomery B., Corey E., Nelson P. S., Vessella R. L., Morrissey C., Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 2013 73 9 932 940 2-s2.0-84878327349 10.1002/pros.22639
13. Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J. L., Vinholes J. J., Goas J. A., Zheng M., Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute 2004 96 11 879 882 2-s2.0-2942518111 (Pubitemid 38807610)
14. Del Fattore A., Teti A., Rucci N., Bone cells and the mechanisms of bone remodelling. Frontiers in Bioscience 2012 4 2302 2321 2-s2.0-84860864038
15. Grigoriadis A. E., Heersche J. N. M., Aubin J. E., Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. Journal of Cell Biology 1988 106 6 2139 2151 2-s2.0-0023787477
16. van de Wijngaert F. P., Tas M. C., Burger E. H., Conditioned medium of fetal mouse long bone rudiments stimulates the formation of osteoclat precursor-like cells from mouse bone marrow. Bone 1989 10 1 61 68 2-s2.0-0024333226 (Pubitemid 19134746)
17. Tondravi M. M., McKercher S. R., Anderson K., Erdmann J. M., Quiroz M., Maki R., Teitelbaum S. L., Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997 386 6620 81 84 2-s2.0-0030933226 10.1038/386081a0 (Pubitemid 27130924)
18. Lacey D. L., Timms E., Tan H.-L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.-X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., Boyle W. J., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 2 165 176 2-s2.0-0032540319 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
19. Lu S. Y., Li M., Lin Y. L., Mitf induction by RANKL is critical for osteoclastogenesis. Molecular Biology of the Cell 2010 21 10 1763 1771 10.1091/mbc.E09-07-0584
20. Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nature Reviews Immunology 2007 7 292 304 10.1038/nri2062 (Pubitemid 46480961)
21. Kular J., Tickner J., Chim S. M., Xu J., An overview of the regulation of bone remodelling at the cellular level. Clinical Biochemistry 2012 45 12 863 873 10.1016/j.clinbiochem.2012.03.021
22. de Bono J. S., Oudard S., Ozguroglu M., Hansen S., MacHiels J., Kocak I., Gravis G., Bodrogi I., MacKenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 2010 376 9747 1147 1154 2-s2.0-77957682309 10.1016/S0140-6736(10)61389-X
23. Jaeger E. B., Samant R. S., Rinker-Schaeffer C. W., Metastasis suppression in prostate cancer. Cancer and Metastasis Reviews 2001 20 3-4 279 286 2-s2.0-0035740011 10.1023/A:1015587411668 (Pubitemid 34595271)
24. Hart I. R., Fidler I. J., Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Research 1980 40 7 2281 2287 2-s2.0-0018875604 (Pubitemid 10082239)
25. Nicolson G. L., Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer and Metastasis Reviews 1988 7 2 143 188 2-s2.0-0024025705 10.1007/BF00046483
26. Weilbaecher K. N., Guise T. A., McCauley L. K., Cancer to bone: a fatal attraction. Nature Reviews Cancer 2011 11 411 425 10.1038/nrc3055
27. Koeneman K. S., Yeung F., Chung L. W., Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999 39 4 246 261 (Pubitemid 29244499)
28. Rucci N., Teti A., Osteomimicry: how tumor cells try to deceive the bone. Frontiers in Bioscience 2010 2 3 907 915 2-s2.0-77956643639
29. Kaplan-Lefko P. J., Chen T., Ittmann M. M., Barrios R. J., Ayala G. E., Huss W. J., Maddison L. A., Foster B. A., Greenberg N. M., Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003 55 3 219 237 2-s2.0-0038415024 10.1002/pros.10215 (Pubitemid 36532401)
30. Masumori N., Thomas T. Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R. M., Tsukamoto T., Shappell S. B., Matusik R. J., A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 2001 61 5 2239 2249 2-s2.0-0035266381 (Pubitemid 32692054)
31. Harper C. E., Patel B. B., Cook L. M., Wang J., Shirai T., Eltoum I. A., Lamartiniere C. A., Characterization of SV-40 Tag rats as a model to study prostate cancer. BMC Cancer 2009 9 30 2-s2.0-60749084422 10.1186/1471-2407-9-30
32. Isaacs J. T., Isaacs W. B., Feitz W. F. J., Scheres J., Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986 9 3 261 281 2-s2.0-0023025173 (Pubitemid 17215900)
33. Gingrich J. R., Barrios R. J., Morton R. A., Boyce B. F., DeMayo F. J., Finegold M. J., Angelopoulou R., Rosen J. M., Greenberg N. M., Metastatic prostate cancer in a transgenic mouse. Cancer Research 1996 56 18 4096 4102 2-s2.0-0029832290 (Pubitemid 26304996)
34. Wang M., Stearns M. E., Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 1991 48 2 115 125 2-s2.0-0025998316
35. Shevrin D. H., Gorny K. I., Kukreja S. C., Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate 1989 15 2 187 194 2-s2.0-0024423556 (Pubitemid 19262147)
36. Shevrin D. H., Kukreja S. C., Ghosh L., Lad T. E., Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clinical and Experimental Metastasis 1988 6 5 401 409 2-s2.0-0023747344
37. Nemeth J. A., Harb J. F., Barroso U. Jr., He Z., Grignon D. J., Cher M. L., Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Research 1999 59 8 1987 1993 2-s2.0-0033561535 (Pubitemid 29186176)
38. Kjønniksen I., Winderen M., Bruland Ø., Fodstad Ø., Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Research 1994 54 7 1715 1719 2-s2.0-0028220206 (Pubitemid 24116175)
39. Arguello F., Baggs R. B., Frantz C. N., A murine model of experimental metastasis to bone and bone marrow. Cancer Research 1988 48 23 6876 6881 2-s2.0-0024262906 (Pubitemid 19012221)
40. Pettaway C. A., Pathak S., Greene G., Ramirez E., Wilson M. R., Killion J. J., Fidler I. J., Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clinical Cancer Research 1996 2 9 1627 1636 2-s2.0-0030223057 (Pubitemid 126447459)
41. Angelucci A., Gravina G. L., Rucci N., Festuccia C., Muzi P., Vicentini C., Teti A., Bologna M., Evaluation of metastatic potential in prostate carcinoma: an in vivo model. International Journal of Oncology 2004 25 6 1713 1720 2-s2.0-16644396019
42. Thalmann G. N., Anezinis P. E., Chang S., Zhau H. E., Kim E. E., Hopwood V. L., Pathak S., Von Eschenbach A. C., Chung L. W. K., Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research 1994 54 10 2577 2581 2-s2.0-0028272478 (Pubitemid 24173741)
43. Wu T. T., Sikes R. A., Cui Q., Thalmann G. N., Kao C., Murphy C. F., Yang H., Zhau H. E., Balian G., Chung L. W., Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. International Journal of Cancer 1998 77 6 887 894 (Pubitemid 28378138)
44. Corey E., Quinn J. E., Bladou F., Brown L. G., Roudier M. P., Brown J. M., Buhler K. R., Vessella R. L., Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002 52 1 20 33 2-s2.0-0036604237 10.1002/pros.10091 (Pubitemid 34553189)
45. Zhau H. E., Li C., Chung L. W. K., Establishment of human prostate carcinoma skeletal metastasis models. Cancer 2000 88 12 2995 3001 2-s2.0-0034659857 (Pubitemid 30413182)
46. Larson S. R., Chin J., Zhang X., Brown L. G., Coleman I. M., Lakely B., Tenniswood M., Corey E., Nelson P. S., Vessella R. L., Morrissey C., Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clinical & Experimental Metastasis 2014 31 2 247 256 10.1007/s10585-013-9625-2
47. Ibrahim T., Flamini E., Mercatali L., Sacanna E., Serra P., Amadori D., Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010 116 6 1406 1418 10.1002/cncr.24896
48. Kasperk C. H., Börcsök I., Schairer H. U., Schneider U., Nawroth P. P., Niethard F. U., Ziegler R., Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcified Tissue International 1997 60 4 368 374 2-s2.0-0343416980 10.1007/s002239900245 (Pubitemid 27143452)
49. Li Y., Cozzi P. J., Targeting uPA/uPAR in prostate cancer. Cancer Treatment Reviews 2007 33 6 521 527 2-s2.0-34548414532 10.1016/j.ctrv.2007.06. 003 (Pubitemid 47355340)
50. Josson S., Matsuoka Y., Chung L. W., Zhau H. E., Wang R., Tumor-stroma co-evolution in prostate cancer progression and metastasis. Seminars in Cell & Developmental Biology 2010 21 1 26 32 10.1016/j.semcdb.2009.11.016
51. Chanda D., Isayeva T., Kumar S., Hensel J. A., Sawant A., Ramaswamy G., Siegal G. P., Beatty M. S., Ponnazhagan S., Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research 2009 15 23 7175 7185 2-s2.0-73149125525 10.1158/1078-0432.CCR-09-1938
52. Fritz V., Brondello J. M., Gordeladze J. O., Reseland J. E., Bony C., Yssel H., Noãl D., Jorgensen C., Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. Journal of Cellular Biochemistry 2011 112 11 3234 3245 2-s2.0-80055023959 10.1002/jcb.23258
53. Spaeth E. L., Labaff A. M., Toole B. P., Klopp A., Andreeff M., Marini F. C., Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Research 2013 73 5347 5359 10.1158/0008-5472.CAN-13-0087
54. Jung Y., Kim J. K., Shiozawa Y., Wang J., Mishra A., Joseph J., Berry J. E., McGee S., Lee E., Sun H., Wang J., Jin T., Zhang H., Dai J., Krebsbach P. H., Keller E. T., Pienta K. J., Taichman R. S., Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications 2013 4 1795 2-s2.0-84877724314 10.1038/ncomms2766
55. Li X., Sterling J. A., Fan K., Vessella R. L., Shyr Y., Hayward S. W., Matrisian L. M., Bhowmick N. A., Loss of TGF- β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/ osteolytic bone lesions. Molecular Cancer Research 2012 10 4 494 503 2-s2.0-84859827014 10.1158/1541-7786.MCR-11-0506
56. Li X., Placencio V., Iturregui J. M., Uwamariya C., Sharif-Afshar A.-R., Koyama T., Hayward S. W., Bhowmick N. A., Prostate tumor progression is mediated by a paracrine TGF- β /Wnt3a signaling axis. Oncogene 2008 27 56 7118 7130 2-s2.0-58149215849 10.1038/onc.2008.293
57. Sung S. Y., Hsieh C. L., Law A., Zhau H. E., Pathak S., Multani A. S., Lim S., Coleman I. M., Wu L., Figg W. D., Dahut W. L., Nelson P., Lee J. K., Amin M. B., Lyles R., Johnstone P. A. J., Marshall F. F., Chung L. W. K., Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Research 2008 68 23 9996 10003 2-s2.0-57149112529 10.1158/0008-5472.CAN-08-2492
58. Tokuda Y., Satoh Y., Fujiyama C., Toda S., Sugihara H., Masaki Z., Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU International 2003 91 7 716 720 2-s2.0-0037568482 10.1046/j.1464-410X.2003. 04218.x (Pubitemid 36583750)
59. Gimble J. M., Nuttall M. E., Bone and fat: old questions, new insights. Endocrine 2004 23 2-3 183 188 2-s2.0-4243137398 10.1385/ENDO:23:2-3:183 (Pubitemid 39140232)
60. Brown M. D., Hart C. A., Gazi E., Bagley S., Clarke N. W., Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. British Journal of Cancer 2006 94 6 842 853 2-s2.0-33645296034 10.1038/sj.bjc.6603030
61. Gazi E., Gardner P., Lockyer N. P., Hart C. A., Brown M. D., Clarke N. W., Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. Journal of Lipid Research 2007 48 8 1846 1856 2-s2.0-34548178349 10.1194/jlr.M700131-JLR200 (Pubitemid 47312000)
62. Angelucci A., Garofalo S., Speca S., Bovadilla A., Gravina G. L., Muzi P., Vicentini C., Bologna M., Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocrine-Related Cancer 2008 15 1 91 100 2-s2.0-41349117825 10.1677/ERC-07-0100 (Pubitemid 351449730)
63. Tannock I. F., De Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 2004 351 15 1502 1512 2-s2.0-4744366279 10.1056/NEJMoa040720 (Pubitemid 39315317)
64. Parker C., Nilsson D Heinrich S., Helle S. I., O'Sullivan J. M., Fosså S. D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D. C., Hoskin P., Bottomley D., James N. D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall'Oglio M., Franzén L., Coleman R., Vogelzang N. J., O'Bryan-Tear C. G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø. S., Sartor O., Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine 2013 369 3 213 223 2-s2.0-84880428467 10.1056/NEJMoa1213755
65. Rogers M. J., New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design 2003 9 32 2643 2658 2-s2.0-0242503684 10.2174/1381612033453640 (Pubitemid 37456015)
66. Roelofs A. J., Thompson K., Gordon S., Rogers M. J., Molecular mechanisms of action of bisphosphonates: current status. Clinical Cancer Research 2006 12 6222s 6230s 10.1158/1078-0432.CCR-06-0843 (Pubitemid 44703794)
67. Hatounl H. T., Lin S., Smith M. R., Barghout V., Upton A., Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases analysis of a national medical claims database. Cancer 2008 113 6 1438 1445 2-s2.0-53149089426 10.1002/cncr.23775
68. Saad F., Lattouf J., Bisphosphonates: prevention of bone metastases in prostate cancer. Recent Results in Cancer Research 2012 192 109 126 2-s2.0-84858236510 10.1007/978-3-642-21892-7-5
69. Polascik T. J., Given R. W., Metzger C., Julian S. R., Vestal J. C., Karlin G. S., Barkley C. S., Bilhartz D. L., McWhorter L. T., Lacerna L. V., Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005 66 5 1054 1059 2-s2.0-27744540396 10.1016/j.urology. 2005.05.035 (Pubitemid 41587160)
70. von Moos R., Body J., Egerdie B., Stopeck A., Brown J. E., Damyanov D., Fallowfield L. J., Marx G., Cleeland C. S., Patrick D. L., Palazzo F. G., Qian Y., Braun A., Chung K., Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer 2013 21 12 3497 3507 2-s2.0-84882444039 10.1007/s00520-013-1932-2
71. Schwarz E. M., Ritchlin C. T., Clinical development of anti-RANKL therapy. rthritis Research & Therapy 2007 9 supplement 1 S7
72. Branstetter D. G., Nelson S. D., Manivel J. C., Blay J. Y., Chawla S., Thomas D. M., Jun S., Jacobs I., Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clinical Cancer Research 2012 18 4415 4424 10.1158/1078-0432.CCR-12-0578
73. Fizazi K., Lipton A., Mariette X., Body J., Rahim Y., Gralow J. R., Gao G., Wu L., Sohn W., Jun S., Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009 27 10 1564 1571 2-s2.0-63749094012 10.1200/JCO.2008.19.2146
74. Orwoll E., Teglbjærg C. S., Langdahl B. L., Chapurlat R., Czerwinski E., Kendler D. L., Reginster J., Kivitz A., Lewiecki E. M., Miller P. D., Bolognese M. A., McClung M. R., Bone H. G., Ljunggren Ö., Abrahamsen B., Gruntmanis U., Yang Y., Wagman R. B., Siddhanti S., Grauer A., Hall J. W., Boonen S., A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. Journal of Clinical Endocrinology and Metabolism 2012 97 9 3161 3169 2-s2.0-84866160239 10.1210/jc.2012-1569
75. Gartrell B. A., Coleman R. E., Fizazi K., Miller K., Saad F., Sternberg C. N., Galsky M. D., Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer. European Urology 2014 65 2 278 286 10.1016/j.eururo.2013.05.015
76. Shen H. C., Shanmugasundaram K., Simon N. I., Cai C., Wang H., Chen S., Balk S. P., Rigby A. C., In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Molecular Endocrinology 2012 26 11 1836 1846 2-s2.0-84868089097 10.1210/me.2012-1222
77. Scher H. I., Fizazi K., Saad F., Taplin M., Sternberg C. N., Miller K., De Wit R., Mulders P., Chi K. N., Shore N. D., Armstrong A. J., Flaig T. W., Fléchon A., Mainwaring P., Fleming M., Hainsworth J. D., Hirmand M., Selby B., Seely L., De Bono J. S., Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012 367 13 1187 1197 2-s2.0-84866770294 10.1056/NEJMoa1207506
78. Fizazi K., Scher H. I., Molina A., Logothetis C. J., Chi K. N., Jones R. J., Staffurth J. N., North S., Vogelzang N. J., Saad F., Mainwaring P., Harland S., Goodman O. B., Sternberg C. N., Li J. H., Kheoh T., Haqq C. M., de Bono J. S., Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 2012 13 10 983 992 2-s2.0-84866948935 10.1016/S1470-2045(12)70379-0
79. Ryan C. J., Smith M. R., De Bono J. S., Molina A., Logothetis C. J., De Souza P., Fizazi K., Mainwaring P., Piulats J. M., Ng S., Carles J., Mulders P. F. A., Basch E., Small E. J., Saad F., Schrijvers D., Van Poppel H., Mukherjee S. D., Suttmann H., Gerritsen W. R., Flaig T. W., George D. J., Yu E. Y., Efstathiou E., Pantuck A., Winquist E., Higano C. S., Taplin M., Park Y., Kheoh T., Griffin T., Scher H. I., Rathkopf D. E., Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 2013 368 2 138 148 2-s2.0-84872078210 10.1056/NEJMoa1209096
80. Dijksterhuis J. P., Petersen J., Schulte G., WNT/Frizzled signaling: receptor-ligand selectivity with focus on FZD-G protein signaling and its physiological relevance. British Journal of Pharmacology 2014 171 5 1195 1209 10.1111/bph.12364
81. Holland J. D., Klaus A., Garratt A. N., Birchmeier W., Wnt signaling in stem and cancer stem cells. Current Opinion in Cell Biology 2013 25 2 254 264 10.1016/j.ceb.2013.01.004
82. Surana R., Sikka S., Cai W., Shin E. M., Warrier S. R., Tan H. J., Arfuso F., Fox S. A., Dharmarajan A. M., Kumar A. P., Secreted frizzled related proteins: implications in cancers. Biochimica et Biophysica Acta 2014 1845 1 53 65 10.1016/j.bbcan.2013.11.004
83. Clevers H., Wnt/beta-catenin signaling in development and disease. Cell 2006 127 3 469 480 10.1016/j.cell.2006.10.018 (Pubitemid 44647433)
84. Hay E., Faucheu C., Suc-Royer I., Touitou R., Stiot V., Vayssière B., Baron R., Roman-Roman S., Rawadi G., Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. Journal of Biological Chemistry 2005 280 14 13616 13623 2-s2.0-17044462159 10.1074/jbc.M411999200 (Pubitemid 40517255)
85. Boyden L. M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M. A., Wu D., Insogna K., Lifton R. P., High bone density due to a mutation in LDL-receptor-related protein 5. New England Journal of Medicine 2002 346 20 1513 1521 2-s2.0-0037118285 10.1056/NEJMoa013444 (Pubitemid 34755690)
86. Gong Y., Gong Y., Slee R. B., Slee R. B., Fukai N., Fukai N., Rawadi G., Rawadi G., Roman-Roman S., Roman-Roman S., Reginato A. M., Reginato A. M., Wang H., Wang H., Cundy T., Cundy T., Glorieux F. H., Glorieux F. H., Lev D., Lev D., Zacharin M., Zacharin M., Oexle K., Oexle K., Marcelino J., Marcelino J., Suwairi W., Suwairi W., Heeger S., Heeger S., Sabatakos G., Sabatakos G., Apte S., Apte S., Adkins W. N., Adkins W. N., Allgrove J., Allgrove J., Arslan-Kirchner M., Arslan-Kirchner M., Batch J. A., Batch J. A., Beighton P., Beighton P., Black G. C. M., Black G. C. M., Boles R. G., Boles R. G., Boon L. M., Boon L. M., Borrone C., Borrone C., Brunner H. G., Brunner H. G., Carle G. F., Carle G. F., Dallapiccola B., Dallapiccola B., De Paepe A., De Paepe A., Floege B., Floege B., Halfhide M. L., Halfhide M. L., Hall B., Hall B., Hennekam R. C., Hennekam R. C., Hirose T., Hirose T., Jans A., Jans A., Jüppner H., Jüppner H., Kim C. A., Kim C. A., Keppler-Noreuil K., Keppler-Noreuil K., Kohlschuetter A., Kohlschuetter A., LaCombe D., LaCombe D., Lambert M., Lambert M., Lemyre E., Lemyre E., Letteboer T., Letteboer T., Peltonen L., Peltonen L., Ramesar R. S., Ramesar R. S., Romanengo M., Romanengo M., Somer H., Somer H., Steichen-Gersdorf E., Steichen-Gersdorf E., Steinmann B., Steinmann B., Sullivan B., Sullivan B., Superti-Furga A., Superti-Furga A., Swoboda W., Swoboda W., Van den Boogaard M.-J., Van den Boogaard M., Van Hul W., Van Hul W., Vikkula M., Vikkula M., Votruba M., Votruba M., Zabel B., Zabel B., Garcia T., Garcia T., Baron R., Baron R., Olsen B. R., Olsen B. R., Warman M. L., Warman M. L., LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001 107 4 513 523 2-s2.0-18044386744 10.1016/S0092-8674(01)00571-2 (Pubitemid 33152786)
87. Wang Y., Li Y. P., Paulson C., Shao J. Z., Zhang X., Wu M., Chen W., Wnt and the Wnt signaling pathway in bone development and disease. Frontiers in Bioscience 2014 19 379 407 10.2741/4214
88. Kawano Y., Kypta R., Secreted antagonists of the Wnt signalling pathway. Journal of Cell Science 2003 116 2627 2634 10.1242/jcs.00623 (Pubitemid 36857216)
89. Hall C. L., Daignault S. D., Shah R. B., Pienta K. J., Keller E. T., Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008 68 13 1396 1404 2-s2.0-50949117119 10.1002/pros.20805
90. Hall C. L., Bafico A., Dai J., Aaronson S. A., Keller E. T., Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research 2005 65 17 7554 7560 2-s2.0-24744439747 10.1158/0008-5472.CAN-05-1317 (Pubitemid 41297224)
91. Zheng D., Decker K. F., Zhou T., Chen J., Qi Z., Jacobs K., Weilbaecher K. N., Corey E., Long F., Jia L., Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Molecular Cancer Research 2013 11 482 493 10.1158/1541-7786.MCR-12-0520
92. Qiao L., Xu Z., Zhao T., Ye L., Zhang X., Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Letters 2008 269 1 67 77 2-s2.0-49349100584 10.1016/j.canlet.2008.04.032
93. Angelucci A., Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. Current Cancer Drug Targets 2009 9 1 1 18 2-s2.0-62549119577 10.2174/156800909787314048
94. Joensuu H., Bono P., Kataja V., Alanko T., Kokko R., Asola R., Utriainen T., Turpeenniemi-Hujanen T., Jyrkkiö S., Möykkynen K., Helle L., Ingalsuo S., Pajunen M., Huusko M., Salminen T., Auvinen P., Leinonen H., Leinonen M., Isola J., Kellokumpu-Lehtinen P., Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. Journal of Clinical Oncology 2009 27 34 5685 5692 2-s2.0-73349115249 10.1200/JCO.2008.21.4577
95. Worthylake R., Opresko L. K., Wiley H. S., ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. Journal of Biological Chemistry 1999 274 13 8865 8874 2-s2.0-0033605560 10.1074/jbc.274.13.8865 (Pubitemid 29164687)
96. Angelucci A., Gravina G. L., Rucci N., Millimaggi D., Festuccia C., Muzi P., Teti A., Vicentini C., Bologna M., Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer 2006 13 1 197 210 2-s2.0-33645990004 10.1677/erc.1.01100
97. Angelucci A., Festuccia C., Gravina G. L., Muzi P., Bonghi L., Vicentini C., Bologna M., Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004 59 2 157 166 2-s2.0-1842631409 10.1002/pros.20008 (Pubitemid 38481227)
98. Zhu J., Jia X., Xiao G., Kang Y., Partridge N. C., Qin L., EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. Journal of Biological Chemistry 2007 282 37 26656 26664 2-s2.0-34848827653 10.1074/jbc.M705064200 (Pubitemid 47501956)
99. Normanno N., De Luca A., Aldinucci D., Maiello M. R., Mancino M., D'Antonio A., De Filippi R., Pinto A., Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocrine-Related Cancer 2005 12 2 471 482 2-s2.0-21244450719 10.1677/erc.1.00956 (Pubitemid 40896460)
100. Qin B. M., Chen X., De Zhu J., Pei D. Q., Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Research 2005 15 3 212 217 2-s2.0-27844589038 10.1038/sj.cr.7290289 (Pubitemid 41653946)
101. Borghese C., Cattaruzza L., Pivetta E., Normanno N., De Luca A., Mazzucato M., Celegato M., Colombatti A., Aldinucci D., Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. Journal of Cellular Biochemistry 2013 114 5 1135 1144 2-s2.0-84875127355 10.1002/jcb.24456
102. De Luca A., Gallo M., Aldinucci D., Ribatti D., Lamura L., D'Alessio A., De Filippi R., Pinto A., Normanno N., Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. Journal of Cellular Physiology 2011 226 8 2131 2138 2-s2.0-79955096087 10.1002/jcp.22548
103. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E. T., Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research 2005 65 18 8274 8285 2-s2.0-24944480253 10.1158/0008-5472.CAN-05-1891 (Pubitemid 41330592)
104. Rentsch C. A., Cecchini M. G., Thalmann G. N., Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. Swiss Medical Weekly 2009 139 15-16 220 225 2-s2.0-67449094018
105. Mishra S., Tang Y., Wang L., Degraffenried L., Yeh I., Werner S., Troyer D., Copland J. A., Sun L., Blockade of transforming growth factor-beta (TGF β) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate 2011 71 13 1441 1454 2-s2.0-79961038278 10.1002/pros.21361
106. Baselga J., Rothenberg M. L., Tabernero J., Seoane J., Daly T., Cleverly A., Berry B., Rhoades S. K., Ray C. A., Fill J., Farrington D. L., Wallace L. A., Yingling J. M., Lahn M., Arteaga C., Carducci M., TGF- β signalling-related markers in cancer patients with bone metastasis. Biomarkers 2008 13 2 217 236 2-s2.0-39149139338 10.1080/13547500701676019 (Pubitemid 351250367)
107. Vo B. T., Morton D. Jr., Komaragiri S., Millena A. C., Leath C., Khan S. A., TGF- β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 2013 154 5 1768 1779 2-s2.0-84876775243 10.1210/en.2012-2074
108. Darrington E., Zhong M., Vo B., Khan S. A., Vascular endothelial growth factor A, secreted in response to transforming growth factor- β 1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. Asian Journal of Andrology 2012 14 5 745 751 2-s2.0-84866265028 10.1038/aja.2011.197
109. Rosano L., Spinella F., Bagnato A., Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer 2013 13 637 651 10.1038/nrc3546
110. Nelson J. B., Chan-Tack K., Hedican S. P., Magnuson S. R., Opgenorth T. J., Bova G. S., Simons J. W., Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Research 1996 56 4 663 668 2-s2.0-0030047858 (Pubitemid 26059878)
111. Bagnato A., Loizidou M., Pflug B. R., Curwen J., Growcott J., Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology 2011 163 2 220 233 2-s2.0-79954456308 10.1111/j.1476-5381.2011. 01217.x
112. Chiao J. W., Moonga B. S., Yang Y. M., Kancherla R., Mittelman A., Wu-Wong J. R., Ahmed T., Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer 2000 83 3 360 365 2-s2.0-0033919232 (Pubitemid 30453577)
113. Yin J. J., Mohammad K. S., Käkönen S. M., Harris S., Wu-Wong J. R., Wessale J. L., Padley R. J., Garrett I. R., Chirgwin J. M., Guise T. A., A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America 2003 100 19 10954 10959 2-s2.0-0141479984 10.1073/pnas.1830978100 (Pubitemid 37140134)
114. Clines G. A., Mohammad K. S., Bao Y., Stephens O. W., Suva L. J., Shaughnessy J. D. Jr., Fox J. W., Chirgwin J. M., Guise T. A., Dickkopf homolog
115. Kane N., Jones M., Brosens J. J., Saunders P. T. K., Kelly R. W., Critchley H. O. D., Transforming growth factor- β 1 attenuates expression of both the progesterone receptor and dickkopf in differentiated human endometrial stromal cells. Molecular Endocrinology 2008 22 3 716 728 2-s2.0-40849106685 10.1210/me.2007-0316 (Pubitemid 351397797)
116. Carlinfante G., Vassiliou D., Svensson O., Wendel M., Heinegård D., Andersson G., Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clinical and Experimental Metastasis 2003 20 5 437 444 2-s2.0-0043238919 10.1023/A:1025419708343 (Pubitemid 37108430)
117. Waltregny D., Bellahcène A., Van Riet I., Fisher L. W., Young M., Fernandez P., Dewé W., De Leval J., Castronovo V., Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. Journal of the National Cancer Institute 1998 90 13 1000 1008 2-s2.0-0032126225 (Pubitemid 28340442)
118. Yeung F., Law W. K., Yeh C. H., Westendorf J. J., Zhang Y., Wang R., Kao C., Chung L. W., Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. Journal of Biological Chemistry 2002 277 2468 2476 10.1074/jbc.M105947200 (Pubitemid 34953269)
119. Bellahcène A., Castronovo V., Ogbureke K. U. E., Fisher L. W., Fedarko N. S., Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nature Reviews Cancer 2008 8 3 212 226 2-s2.0-39749187284 10.1038/nrc2345 (Pubitemid 351301854)
120. Fedarko N. S., Jain A., Karadag A., Van Eman M. R., Fisher L. W., Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research 2001 7 12 4060 4066 2-s2.0-0035671826 (Pubitemid 34044628)
121. Gimba E. R., Tilli T. M., Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Letters 2013 331 1 11 17 10.1016/j.canlet.2012.12.003
122. Craig A. M., Bowden G. T., Chambers A. F., Spearman M. A., Greenberg A. H., Wright J. A., McLeod M., Denhardt D. T., Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metatatic potential of murine fibroblasts. International Journal of Cancer 1990 46 1 133 137 2-s2.0-0025287017 10.1002/ijc.2910460124 (Pubitemid 20225799)
123. Yamate T., Mocharla H., Taguchi Y., Igietseme J. U., Manolagas S. C., Abe E., Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. Endocrinology 1997 138 7 3047 3055 2-s2.0-0030924823 10.1210/en.138.7.3047 (Pubitemid 27258540)
124. Pampena D. A., Robertson K. A., Litvinova O., Lajoie G., Goldberg H. A., Hunter G. K., Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochemical Journal 2004 378 3 1083 1087 2-s2.0-1642422853 10.1042/BJ20031150 (Pubitemid 38406890)
125. Yoshitake H., Rittling S. R., Denhardt D. T., Noda M., Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proceedings of the National Academy of Sciences of the United States of America 1999 96 14 8156 8160 2-s2.0-0033529194 10.1073/pnas.96.14.8156 (Pubitemid 29328424)
126. Ishijima M., Rittling S. R., Yamashita T., Tsuji K., Kurosawa H., Nifuji A., Denhardt D. T., Noda M., Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. Journal of Experimental Medicine 2001 193 3 399 404 2-s2.0-0035808779 10.1084/jem.193.3.399 (Pubitemid 32524523)
127. Akech J., Wixted J. J., Bedard K., Van Der Deen M., Hussain S., Guise T. A., Van Wijnen A. J., Stein J. L., Languino L. R., Altieri D. C., Pratap J., Keller E., Stein G. S., Lian J. B., Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010 29 6 811 821 2-s2.0-76849112495 10.1038/onc.2009.389
128. Angelucci A., Festuccia C., D'Andrea G., Teti A., Bologna M., Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biological Chemistry 2002 383 1 229 234 2-s2.0-0036005977 10.1515/BC.2002.024 (Pubitemid 34224046)
129. Lee J. L., Wang M. J., Sudhir P. R., Chen G. D., Chi C. W., Chen J. Y., Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Research 2007 67 5 2089 2097 2-s2.0-33947254565 10.1158/0008-5472.CAN-06-3625 (Pubitemid 46424227)
130. Xu L., Anderson A. L., Lu Q., Wang J., Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation. Biomaterials 2007 28 4 750 761 2-s2.0-33750432152 10.1016/j.biomaterials.2006.09.022 (Pubitemid 44647453)
131. Valverde P., Tu Q., Chen J., BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Journal of Bone and Mineral Research 2005 20 9 1669 1679 2-s2.0-24144485800 10.1359/JBMR.050511 (Pubitemid 41243555)
132. Gordon J. A., Sodek J., Hunter G. K., Goldberg H. A., Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. Journal of Cellular Biochemistry 2009 107 6 1118 1128 2-s2.0-68049112306 10.1002/jcb.22211
133. Waltregny D., Bellahcène A., De Leval X., Florkin B., Weidle U., Castronovo V., Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. Journal of Bone and Mineral Research 2000 15 5 834 843 2-s2.0-0034055420 (Pubitemid 30233406)
134. Pécheur I., Peyruchaud O., Serre C., Guglielmi J., Voland C., Bourre F., Margue C., Cohen-Solal M., Buffet A., Kieffer N., Clézardin P., Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. The FASEB Journal 2002 16 10 1266 1268 2-s2.0-0036676419
135. Sung V., Stubbs J. T. III, Fisher L., Aaron A. D., Thompson E. W., Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. Journal of Cellular Physiology 1998 176 3 482 494 (Pubitemid 28383909)
136. Thomas R., True L. D., Bassuk J. A., Lange P. H., Vessella R. L., Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research 2000 6 3 1140 1149 2-s2.0-0034019916 (Pubitemid 30159378)
137. Jacob K., Webber M., Benayahu D., Kleinman H. K., Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Research 1999 59 17 4453 4457 2-s2.0-0033199111 (Pubitemid 29418768)
138. De S., Chen J., Narizhneva N. V., Heston W., Brainard J., Sage E. H., Byzova T. V., Molecular pathway for cancer metastasis to bone. Journal of Biological Chemistry 2003 278 40 39044 39050 2-s2.0-0141643144 10.1074/jbc.M304494200 (Pubitemid 37221807)
139. McCabe N. P., Kerr B. A., Madajka M., Vasanji A., Byzova T. V., Augmented osteolysis in SPARC-deficient mice with bone residing prostate cancer. Neoplasia 2011 13 1 31 39 2-s2.0-78650967989 10.1593/neo.10998
140. Moro L., Arbini A. A., Marra E., Greco M., Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation. Journal of Biological Chemistry 2005 280 23 22482 22491 2-s2.0-20444490365 10.1074/jbc.M414091200 (Pubitemid 40827904)
141. Podgorski I., Linebaugh B. E., Koblinski J. E., Rudy D. L., Herroon M. K., Olive M. B., Sloane B. F., Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. American Journal of Pathology 2009 175 3 1255 1269 2-s2.0-70349241644 10.2353/ajpath.2009.080906
142. Karsenty G., Ferron M., The contribution of bone to whole-organism physiology. Nature 2012 481 314 320 10.1038/nature10763
143. Santagata S., Demichelis F., Riva A., Varambally S., Hofer M. D., Kutok J. L., Kim R., Tang J., Montie J. E., Chinnaiyan A. M., Rubin M. A., Aster J. C., JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 2004 64 19 6854 6857 2-s2.0-4944241544 10.1158/0008-5472.CAN-04-2500 (Pubitemid 39330990)
144. Domingo-Domenech J., Vidal S. J., Rodriguez-Bravo V., Castillo-Martin M., Quinn S. A., Rodriguez-Barrueco R., Bonal D. M., Charytonowicz E., Gladoun N., de la Iglesia-Vicente J., Petrylak D. P., Benson M. C., Silva J. M., Cordon-Cardo C., Suppression of acquired docetaxel resistance in prostate cancer through depletion of Notch- and Hedgehog-dependent tumor-initiating cells. Cancer Cell 2012 22 3 373 388 2-s2.0-84866021276 10.1016/j.ccr.2012.07.016
145. Jung Y., Wang J., Song J., Shiozawa Y., Wang J., Havens A., Wang Z., Sun Y., Emerson S. G., Krebsbach P. H., Taichman R. S., Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 2007 110 1 82 90 2-s2.0-34347400986 10.1182/blood-2006-05-021352 (Pubitemid 47026822)
146. Shiozawa Y., Havens A. M., Jung Y., Ziegler A. M., Pedersen E. A., Wang J., Wang J., Lu G., Roodman G. D., Loberg R. D., Pienta K. J., Taichman R. S., Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. Journal of Cellular Biochemistry 2008 105 2 370 380 2-s2.0-53949112969 10.1002/jcb.21835